Articles tagged with Drug Studies
A church-based program combining faith-based lifestyle change with motivational interviewing significantly lowered systolic blood pressure by 5.8 mm Hg, compared to an educational program alone. The study found that the intervention was effective in improving blood pressure control and could be a routine practice in places of worship.
A new long-acting injectable implant developed by UNC School of Medicine researchers has shown promising results in animal models, delivering anti-HIV medication over time with minimal toxicity. The implant can be quickly and safely removed if needed, making it a potential game-changer for HIV treatment and prevention.
A recent study published in The Journal of the American Osteopathic Association found that long-term oxygen therapy does not decrease hospitalization risk or increase life expectancy for many patients with mild to moderate COPD. However, it may lower quality of life due to its significant costs and practical challenges.
A phase II study led by the University of Texas MD Anderson Cancer Center found that neoadjuvant combination checkpoint blockade produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign of disease at surgery. However, the trial was closed early due to high incidence of side effects.
Researchers found no clear evidence that statins benefit patients with non-Cardiovascular Disease (CVD) conditions, except for preventing deaths from kidney disease. Statins may also slow cancer progression, but further investigation is needed.
A clinical trial suggests that individuals with bipolar disorder who have a high-quality diet, low BMI, or anti-inflammatory properties may respond better to nutraceutical treatment. The study found statistically significant results but emphasizes the need for replication in larger trials before firm conclusions can be drawn.
The new guidelines update previous recommendations, prioritizing patient-centric care, medication adherence, and lifestyle management. They also highlight the importance of metabolic surgery, metformin as first-line therapy, and personalized medication selection based on patient preferences and comorbidities.
A study of 44,832 Medicare patients found that disruption in their regular combination inhaled corticosteroid therapy led to a higher rate of costly exacerbations and hospitalizations. Approximately 45% of patients did not receive an ICS/LABA after a formulary block, potentially impacting symptoms and disease control.
A study funded by NIH found that gastric banding is as effective as metformin in stabilizing disease for people with prediabetes or new-onset type 2 diabetes. Participants who underwent gastric banding surgery lost significantly more weight and showed similar improvements in insulin sensitivity compared to those taking metformin.
A pilot study at Aarhus University found that certain migraine patients can reduce medication use by using an inhaler that changes the air's composition. The treatment increases brain oxygen supply by up to 70% and stops the destructive chain reaction, providing significant pain relief.
Most industry-funded clinical trials show funder involvement in design, conduct, and reporting, raising questions about academic freedom and independence. Only a few trials were found to be independent, highlighting the need for accurate reporting of contributorship to ensure patient confidence in trial results.
Researchers at Children's Hospital Los Angeles have developed a proof-of-concept study for treating recurrent metastatic neuroblastoma using dinutuximab and activated natural killer cells. The study showed significant improvement in survival rates, providing a promising lead for a clinical trial.
Scientists at UNIGE discovered that resveratrol, a molecule in grape skin and seeds, can prevent lung cancer in mice treated with a nasal formulation. The study showed a 45% decrease in tumor load and a higher concentration of resveratrol in the lungs after nasal administration.
Scientists at Calibr have built a massive library of existing small-molecule drugs called ReFRAME, which shows promise for treating major diseases such as HIV and tuberculosis. Preliminary testing has identified two additional compounds effective against Cryptosporidium spp., offering a potential therapy for severe diarrhea.
Researchers at the University of Edinburgh discovered a molecule that blocks Otx2 activity, crucial for germ cell development. The study sheds light on the earliest stages of sperm and egg cell formation, offering new insights into the processes governing their separation from other cells.
A phase 1b study and a phase 2 proof of concept study have generated positive results for SNF472, demonstrating a linear pharmacokinetic behavior and improved safety profile. A randomized, placebo-controlled phase 2b study is evaluating the effect of SNF472 on cardiovascular calcification over 1 year in haemodialysis patients.
A new study emphasizes the need for distinct research methods when studying e-cigarettes due to their varying nicotine levels, vaping method, and ability to be started and stopped. This distinction is crucial in understanding the unique risks associated with e-cigarette use, particularly among teens.
A McMaster University-led review of 52 articles found no significant association between progression-free survival and health-related quality of life in cancer patients. The study suggests that clinical trials should measure health-related quality of life directly to ensure patients are receiving effective treatments.
A comparative clinical trial found that delivering corticosteroids directly into the eye is more effective than injecting them adjacent to the eye in treating uveitic macular edema. The treatment led to significant reductions in macular edema and improvements in visual acuity, with intravitreal triamcinolone and dexamethasone implant s...
A recent study has shown that adding genetic factors to existing risk assessments can help predict future major coronary events in people with type 2 diabetes. The genetic score provides a significant improvement in correctly predicting cardiovascular risk, particularly when used early in life.
A new study finds that proton pump inhibitors are associated with a 19% higher risk of hip fractures in dialysis patients, regardless of usage level. Histamine-2 receptor antagonists were not linked to increased fracture risk. The findings highlight the need for individualized assessment and caution in PPI use among hemodialysis patients.
A novel combination of broadly neutralizing antibodies has shown remarkable results in reducing HIV viral loads in infected individuals, even after treatment interruptions. This groundbreaking study suggests a promising approach to antibody-mediated therapy, paving the way for long-term control of the virus.
Researchers have developed a novel immunotherapy that can suppress HIV for months at a time, using a combination of two anti-HIV antibodies. The treatment, called broadly neutralizing antibodies (bNAbs), has shown promising results in clinical trials, with some patients experiencing sustained viral suppression for over four months.
Researchers evaluated the safety of pimavanserin for treating Parkinson's disease psychosis, finding a lower mortality risk compared to quetiapine or combination therapy. The study provides reassurance for clinicians and families but highlights the need for further research on disease severity and cause of death.
A Phase III clinical trial is enrolling men with metastatic Stage 4 prostate cancer to compare standard systemic therapy with or without surgery or radiation therapy. The goal is to delay disease progression and improve survival.
Mesoblast's MPC-150-IM heart failure product candidate is being studied in a randomized trial combining cell injection with corrective surgery in children under five with hypoplastic left heart syndrome. The trial aims to promote cardiac growth and regeneration, improving quality of life and longevity.
The ALTA-1 trial found brigatinib to be a first-line treatment option for advanced ALK-positive non-small cell lung cancer, with a 51% reduction in progression or death risk compared to crizotinib. Patients treated with brigatinib also showed improved response rates and longer progression-free survival.
A large-scale international study published in PLOS Medicine found that a new medication called Nilvadipine showed promise in slowing the progression of mild and moderate Alzheimer's disease. However, the overall group of patients did not benefit from the treatment. Further research is needed to explore its potential.
A new study found that pregabalin, a common painkiller, is not effective in controlling chronic pain after traumatic nerve injury. However, it did show promise in relieving post-surgical pain for patients who underwent certain procedures.
The ReCre8 trial found that a novel polymer-free amphilimus-eluting stent was clinically safe and effective, comparable to a durable polymer zotarolimus-eluting stent. The study showed that one-month DAPT in troponin-negative patients may be safe regarding stent thrombosis.
The BIONYX trial found that the Resolute Onyx stent is safe and effective in a complex patient population, with low rates of cardiac death and target vessel-related myocardial infarction. The stent's improved radiographic visibility facilitates accurate assessment of stent expansion and apposition to the arterial wall.
A recent study published in BMJ reveals that European Union clinical trial registrations are incomplete, with universities struggling to meet regulatory requirements. Pharmaceutical companies, however, show relatively good compliance with EU regulations.
Phase 1 and phase 2 clinical trials of entrectinib in ROS1-positive non-small cell lung cancer demonstrated a response rate of 77.4 percent and median duration of response of 24.6 months. Entrectinib also showed competitive results in patients with brain metastases and poor prognosis
A multicenter clinical trial found that the transcatheter mitral valve repair significantly reduced hospitalizations and mortality for heart failure patients with moderate-to-severe or severe functional mitral regurgitation. The procedure improved symptoms, quality of life, and survival rates.
Researchers at Barrow Neurological Institute have developed a new clinical trial regimen for treating glioblastoma, a complex brain tumor. The study demonstrates the ability of the drug AZD1775 to penetrate brain tissue and provide clinically-relevant activity against human glioblastoma.
Researchers at Baylor College of Medicine found that smaller sample sizes can greatly exaggerate the magnitude of group differences in multisensory integration studies. Studies with sample sizes of 20 or less are more likely to produce inflated results, which can lead to incorrect conclusions and potential failures in therapy development.
A vicious feedback loop drives brain degeneration in Alzheimer's disease, but a clinically approved drug may provide a solution. The study identified Dkk1 as a central player in the cycle, and targeting it with fasudil shows promise in animal models.
A new brain imaging method can accurately diagnose Alzheimer's disease by detecting specific tau protein depositions. The method has shown great sensitivity and specificity in detecting 90-95% of all cases of Alzheimer's, outperforming existing diagnostic methods.
New Zealand research found that infants on proton pump inhibitors (PPIs) are not at higher risk of pneumonia or lower respiratory tract infections. The study of over 21,000 infants dispensed PPIs between 2005 and 2012 revealed a relatively low number of serious lung infections among those using the medication.
Researchers found that targeting IL-1β reduced risk of gout attacks by half, with no change in serum urate levels, suggesting an independent mechanism. The study's findings could lead to new therapeutic avenues for both heart disease and crystal diseases like gout.
The POPULAR study confirms a significant association between neuromuscular blocking agents and respiratory complications after surgery. Established techniques to avoid residual paralysis did not lower the patients' risk of pulmonary complications.
A clinical trial has shown that targeted lung denervation (TLD) reduces chronic respiratory symptoms, exacerbations, and hospitalizations in COPD patients. The procedure involves delivering radiofrequency energy to the nerves on the outside of the airways, causing them to relax and widen.
A systematic review found that healthy infants and children taking probiotics are 29% less likely to receive antibiotics. Probiotics may reduce antibiotic use by reducing the incidence and duration of infections, making them a potential tool for physicians as an alternative to antibiotics.
The study found that prescription rates for ADHD medications are still lower than diagnosis rates worldwide, highlighting disparities in clinical approaches to treating the condition. In contrast, regions like North America have higher medication use rates, but also face concerns of overdiagnosis and overmedication.
A study found that only 49.5% of clinical trials in Europe reported results as required by EU regulations, with commercial sponsors being more likely to comply than non-commercial ones. The researchers also discovered inconsistencies in the EU Clinical Trials Register and developed a website to track compliance.
A new study by Centre for Addiction and Mental Health suggests that an inhaled form of a high blood pressure medication may treat certain types of anxiety as well as pain. The treatment uses a short-acting nasal spray called amiloride, which targets physiological changes in brain functioning linked to anxiety and pain sensitivity.
A new study found that mechanically ventilated patients treated with vasopressor medications have a higher risk of developing ICU-associated weakness. The use of beta-adrenergic receptor-stimulating vasopressors like norepinephrine was associated with a three-fold increase in the odds of developing weakness.
A recent study by Boston Medical Center found that only 24% of youths receive FDA-approved medications for opioid use disorder within three months of diagnosis. Patients who receive medication are more likely to remain in treatment compared to those who only receive behavioral health services.
Two DNA testing programs in Spain and UK successfully matched patient tumor profiles with targeted therapies, enabling new opportunities for personalized medicine. The programs use whole genome sequencing to identify specific genetic features of tumors and match them with early clinical trials.
A new antimalarial drug called DM1157 is being tested in a Phase 1 clinical trial for its safety and efficacy. The trial aims to enroll up to 104 healthy volunteers and assess the drug's impact on the human body.
A recent study found that black adults are at higher risk for dangerous blood pressure spikes, with nearly 90% of those experiencing hypertensive crisis being black. The study also revealed that anemia and chronic kidney disease can increase the risk of hypertensive emergencies.
A new international collaborative study led by Dr. Dick Menzies found that new TB drugs achieve excellent results in treating MDR-TB, demonstrating consistently better cure rates and reduced mortality compared to currently used treatments. The study prompted a complete overhaul of worldwide guidelines for MDR-TB treatment.
Researchers found that varenicline, a medication used to help cigarette smokers quit, had no effect on shisha smokers. Shisha smoking poses similar health risks as cigarette smoking due to inhalation of large volumes of tobacco and charcoal smoke.
A new influenza drug, baloxavir marboxil, has been shown to significantly shorten the duration of flu symptoms in teens and adults, clearing virus more quickly than placebo. The drug's antiviral potency was found to be similar to that of a five-day course of oseltamivir, but with greater effectiveness and no significant side effects.
A pilot study found that transcutaneous electrical nerve stimulation improved arousal, lubrication, and orgasm in women with female sexual dysfunction. Eight out of nine participants reported significant improvements, comparable to or greater than prior studies of different treatments for FSD.
A Phase 1 clinical trial is underway to evaluate the immune-boosting properties of imiquimod cream in combination with an H5N1 influenza vaccine. The study aims to enhance the immune response conferred by the pre-pandemic vaccine, potentially reducing the number of doses required to achieve sufficient immunity.
A new intervention has been found to reduce mortality rates by 50% among people with HIV who inject drugs. The program combines psychosocial counseling, guidance on the healthcare system, and support from systems navigators to increase treatment participation and HIV suppression.
A study published in The Lancet found that telemedical interventional management reduced unplanned hospitalizations by 44% and increased life expectancy for patients with heart failure. Patients who received remote patient management interventions also showed significant reductions in all-cause mortality, regardless of their location.
A simple intervention program increased antiretroviral medication use by 30% among HIV-positive injection-drug users, while also reducing deaths and viral suppression. The flexible program was well-received globally and can be scaled up to improve worldwide health.
The HPTN 074 study demonstrates a significant reduction in mortality and increased antiretroviral therapy usage among participants, leading to improved viral suppression. The integrated intervention combining psychosocial counseling and substance use treatment referrals was associated with enhanced uptake of these services.